Literature DB >> 27363432

Voluntary Second Opinions in Pediatric Bone and Soft Tissue Pathology: A Retrospective Review of 1601 Cases From a Single Mesenchymal Tumor Consultation Service.

Alyaa Al-Ibraheemi1, Andrew L Folpe2.   

Abstract

The diagnosis of bone and soft tissue tumors in children is challenging. These lesions are especially difficult for general pathologists. We reviewed our experience with pediatric mesenchymal tumors sent in consultation to our service, with the goal of identifying issues that most often prompted second-opinion referral. Roughly 16 000 cases were seen in toto, of which 1601 occurred in children. These included 491 bone cases and 1110 soft tissue cases. The cases were referred by private practices/nonacademic medical centers (85%), academic medical centers (8%), and pediatric hospitals (7%). Reasons for referral were (a) self-perceived lack of experience with pediatric mesenchymal tumors (n = 930), (b) second opinion requested by the clinician or patient (n = 132), and (c) perceived or real need for ancillary studies not available at the referring institution (n = 116). The referring pathologists suggested a diagnosis for 670 cases; of these, 476 (71%) were in essential agreement with our final diagnosis. Of the remaining, 139 (21%) were considered "minor disagreements" and 55 (8%) "major disagreements." The "major disagreement" cases could be divided into (a) malignant tumors submitted with benign diagnoses (58%), (b) benign tumors submitted with malignant diagnoses (25%), (c) nonneoplastic conditions submitted as representing neoplasms (11%), and (d) neoplasm submitted as representing nonneoplastic conditions (6%). Pediatric mesenchymal tumors comprised 10% of cases sent to our mesenchymal tumor consultation practice. The rates of diagnostic disagreement found in this study are roughly in accordance with prior studies of mandatory and voluntary second opinion in adult soft tissue tumors. Given the rarity of these tumors, expert second opinion may be of value.
© The Author(s) 2016.

Entities:  

Keywords:  discrepancy; major disagreement; pediatric mesenchymal tumors; sarcoma; second opinion

Mesh:

Year:  2016        PMID: 27363432     DOI: 10.1177/1066896916657591

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  5 in total

1.  Plexiform fibrohistiocytic tumor: a clinicopathological and immunohistochemical study of 39 tumors, with evidence for a CSF1-producing "null cell" population.

Authors:  Judith Jebastin Thangaiah; Nooshin K Dashti; Abbas Agaimy; Karen Fritchie; Andrew L Folpe
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

2.  Cutaneous Ewing Sarcoma Presenting as a Second Primary Malignancy in a Child.

Authors:  Jessica Daley; Nathan Williams; Claudia M Salgado; Charles Schultz; Julia Meade; John Ozolek; Brock Lindsey; Kelly M Bailey
Journal:  J Pediatr Hematol Oncol       Date:  2022-04-14       Impact factor: 1.170

3.  Clinical Routine and Necessary Advances in Soft Tissue Tumor Imaging Based on the ESSR Guideline: Initial Findings.

Authors:  Alexander Korthaus; Sebastian Weiss; Alexej Barg; Johannes Salamon; Carsten Schlickewei; Karl-Heinz Frosch; Matthias Priemel
Journal:  Tomography       Date:  2022-06-17

4.  Obtaining a second opinion is a neglected source of health care inequalities.

Authors:  Jochanan Benbassat
Journal:  Isr J Health Policy Res       Date:  2019-01-16

Review 5.  Surgical Pathology Diagnostic Pitfalls of Hepatoblastoma.

Authors:  Finn Morgan Auld; Consolato M Sergi
Journal:  Int J Surg Pathol       Date:  2022-01-20       Impact factor: 1.358

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.